P&G ALEVE DURATION-OF-ACTION DATA "NOT INCONSISTENT" WITH AD CLAIMS
This article was originally published in The Tan Sheet
Executive Summary
P&G ALEVE DURATION-OF-ACTION DATA "NOT INCONSISTENT" WITH AD CLAIMS, the National Advertising Division of the Council for Better Business Bureaus determined in a Nov. 10 case report. Procter & Gamble's clinical evidence supports claims that "Aleve's analgesic effect will last longer than Tylenol and has a tendency to last longer than ibuprofen," NAD said.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning